Australia  

Mesoblast

Latest news and video coverage curated from trusted media outlets

0
shares
ShareTweetSavePostSend
 

You Might Like


Why Mesoblast (ASX:MSB) and this ASX 200 share have doubled in value in 2020

Here's why Mesoblast limited (ASX:MSB) and this ASX 200 share have more than doubled in value in 2020...
Motley Fool - Published

What Does the Future Hold for the Mesoblast Share Price (ASX:MSB)

Do you want to know who the fastest movers of 2020 have been? Well, they mostly have one thing in common… That’s […]
The Daily Reckoning AUS - Published

The Mesoblast (ASX:MSB) share price surges on award win

The Mesoblast Limited (ASX: MSB) share price surged higher today after winning an industry award. Here's why the biotech company is one to watch
Motley Fool - Published

Why Afterpay, Clinuvel, Mesoblast, & Uniti shares are storming higher

Afterpay Ltd (ASX:APT) and Uniti Group Ltd (ASX:UWL) shares are two of four storming higher on Tuesday. Here's why...
Motley Fool - Published

Is the Mesoblast share price a bargain yet?

The Mesoblast limited (ASX: MSB) share price slumped 5.5% lower on Monday but is the ASX biotech share cheap enough to buy?
Motley Fool - Published

Why the Mesoblast share price jumped higher this morning

Today the Mesoblast share price jumped higher after the company announced a positive recommendation regarding its COVID-19 treatment trials.
Motley Fool - Published

The Mesoblast share price rocketed 40% higher in August: Is it too late to invest?

The Mesoblast limited (ASX:MSB) share price was on fire in August and rocketed 40% higher. Is it too late to buy shares?
Motley Fool - Published

Mesoblast share price flat on Australian phase 3 COVID-19 trial news

The Mesoblast limited (ASX:MSB) share price is trading flat on Wednesday following an update on its COVID-19 trial...
Motley Fool - Published

These were the best performing ASX 200 shares in August

Corporate Travel Management Ltd (ASX:CTD) and Mesoblast limited (ASX:MSB) shares were among the best performing ASX 200 shares in August...
Motley Fool - Published

Mesoblast share price on the rise after delivering promising FY20 results

The Mesoblast share price is on the rise this morning after the company delivered positive FY20 results and sets itself up for FY21.
Motley Fool - Published

Mesoblast revenue up 90 per cent as company waits on product news

The stem cell treatments provider narrowed its losses by 13 per cent ahead of a critical month of news in September.
Brisbane Times - Published Also reported by •Sydney Morning HeraldThe Age

Afterpay and Mesoblast were among the most traded shares on the ASX last week

Afterpay Ltd (ASX:APT) and Mesoblast limited (ASX:MSB) shares were among the most traded shares on the CommSec platform last week.
Motley Fool - Published

S&P/ASX 200 gains 0.32% as new COVID-19 cases decline in Victoria

S&P/ASX 200 (INDEXASX:XJO) has gained 0.32% to 6,096 by 12.51 pm as Victoria confirmed another decline in the number of new COVID-19 cases, from 282 yesterday to 222 today. A number of firms are near..
Proactive Investors - Published

ASX 200 rises 0.6%, Mesoblast soars

The S&P/ASX 200 Index (ASX:XJO) rose by another 0.6% today. The Mesoblast Limited (ASX:MSB) share price went up 39%.
Motley Fool - Published

Why I’d buy today’s CSL share price over Mesoblast

Looking to invest in an ASX biotech? As a long-term investor, here’s why I would buy today's CSL share price rather than Mesoblast.
Motley Fool - Published

ASX 200 up 0.3%: NAB Q3 update, Mesoblast rockets, Newcrest guidance disappoints

National Australia Bank Ltd (ASX:NAB) and Mesoblast limited (ASX:MSB) shares are making waves on the ASX 200 on Friday...
Motley Fool - Published

Mesoblast share price rockets 57% higher on FDA breakthrough

The Mesoblast limited (ASX:MSB) share price is rocketing higher on Friday after making a breakthrough with the FDA in the United States...
Motley Fool - Published

Mesoblast treatment gets US panel's tick of approval

Expert panel has voted in favour of Mesoblast's flagship product for treating children with severe responses to bone marrow transplants. The treatment is also being tested on some COVID-19 patients.
Brisbane Times - Published Also reported by •Sydney Morning HeraldThe Age

Mesoblast share price on watch after US regulatory approval

The Mesoblast Limited (ASX: MSB) share price could be set to surge after gaining a key regulatory approval from the United States.
Motley Fool - Published

5 things to watch on the ASX 200 on Friday

Mesoblast limited (ASX:MSB) and Newcrest Mining Limited (ASX:NCM) shares will be on watch on the ASX 200 on Friday...
Motley Fool - Published

Broker reveals its expectations for the Mesoblast FDA meeting

The Mesoblast limited (ASX:MSB) share price will be one to watch on Friday after it holds its key FDA meeting...
Motley Fool - Published

Down 37% in 2 days! Is the Mesoblast share price a buy?

The Mesoblast Limited (ASX: MSB) share price has slumped 37.0% in just two days, but when will the biotech share be back in the buy zone?
Motley Fool - Published

Why Mesoblast, Northern Star, SEEK, & WiseTech Global shares are sinking lower

SEEK Limited (ASX:SEK) and WiseTech Global Ltd (ASX:WTC) shares are two of four sinking notably lower on Wednesday. Here's why...
Motley Fool - Published

Mesoblast plunges 30 per cent ahead of milestone meeting

The stem cell treatment maker is under pressure as it faces a crucial test to get its flagship drug approved by the US Food and Drug Administration.
Brisbane Times - Published Also reported by •Sydney Morning HeraldThe Age

Why Afterpay, Challenger, IVE Group, & Mesoblast shares are dropping lower

Afterpay Ltd (ASX:APT) and Mesoblast limited (ASX:MSB) shares are two of four dropping notably lower this week. Here's why...
Motley Fool - Published

S&P/ASX 200 gains 1.27% as banks and consumer stocks lift

S&P/ASX 200 (INDEXASX:XJO) has surged 1.27% to 6,081 by 1 pm with all sectors currently in green and the financials out-performing, up 2.36%. National Australia Bank Ltd (ASX:NAB) and Australia and New..
Proactive Investors - Published

ASX 200 jumps 1.2%: Big four banks rise, Qantas update, Mesoblast surges

Qantas Airways Limited (ASX:QAN) and Westpac Banking Corp (ASX:WBC) shares are among the movers and shakers on the ASX 200 on Monday...
Motley Fool - Published

Mesoblast’s share price gained another 16% in July. Here’s why.

Biotechnology company Meosblast's share price continued its run higher in July, gaining more than 16% to reach $3.78 per share.
Motley Fool - Published

Why this broker thinks Mesoblast shares are a strong buy

The Mesoblast limited (ASX:MSB) share price could be heading higher from here according to one Australian broker... The post Why this broker thinks Mesoblast shares are a strong buy appeared first..
Motley Fool - Published


 Page 1  〉